Molecular Classification
Biological process, Immune system pathway, Other
Other Names
Adaptive immune response, Antigen-driven immune activation, Cytokine-mediated adaptive immunity, Antigen presentation pathway
Disease Roles
Autoimmune diseaseCancerInfectious disease

Adaptive immune system via antigen presentation and cytokine induction Overview

The adaptive immune system via antigen presentation and cytokine induction represents a fundamental biological process rather than a single molecular target. It involves the recognition of specific non-self antigens by T and B lymphocytes, a process mediated by professional antigen-presenting cells (APCs) that display peptide fragments on Major Histocompatibility Complex (MHC) molecules (Janeway et al., Immunobiology, 2001). Upon recognition, a cascade of signaling events leads to the induction of cytokines, which act as chemical messengers to coordinate the immune response, promote cell proliferation, and direct effector functions (NCBI, The Immune System, 2023). This system is critical for pathogen clearance and immunological memory, but its dysfunction is a primary driver in many pathologies, including autoimmune diseases where the system attacks host tissues and cancer where the system is often suppressed (Nature Reviews Immunology, 2020). Pharmacological intervention typically focuses on specific nodes within this process, such as blocking pro-inflammatory cytokines like TNF-alpha or modulating T-cell checkpoints like PD-1 to restore or suppress immune activity (PubMed, PMC7358229).

Mechanism of Action

Modulation of T-cell activation, inhibition of cytokine signaling cascades, or blockade of antigen presentation pathways to either suppress or enhance the immune response.

Biological Functions

Immune response
Antigen processing
Cellular signaling
T-cell activation
B-cell maturation

Disease Associations

Autoimmune disease
Cancer
Infectious disease
Inflammatory disorder
Allergy

Safety Considerations

  • Cytokine release syndrome (CRS)
  • Increased susceptibility to opportunistic infections
  • Autoimmune-related adverse events (irAEs)
  • Immunosuppression
  • Anaphylaxis

Interacting Drugs

Pembrolizumab
Adalimumab
Abatacept
Cyclosporine
Infliximab
Nivolumab

Associated Biomarkers

Biomarker
MHC class II expression
Interferon-gamma levels
CD4+/CD8+ T-cell ratios
Interleukin-2 (IL-2) concentration
T-cell receptor (TCR) repertoire diversity